Results 151 to 160 of about 4,520 (170)

Paxlovid for a Patient on a DOAC

2022
openaire   +1 more source

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer

JTO Clinical and Research Reports, 2023
Lee Nguyen, Misako Nagasaka, Sai-Hong Ignatius Ou   +2 more
exaly  

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?

Biomedicine and Pharmacotherapy, 2023
Seyed Mohammadreza Hashemian, Amirhossein Sheida, Mohammad Taghizadieh   +2 more
exaly  

Appraisal of evidence reliability and applicability of Paxlovid as treatment for SARS‐COV‐2 infection: A systematic review

Reviews in Medical Virology, 2023
Changtai Zhu, Xiao-Hua Chen, Shigui Yang   +2 more
exaly  

Pfizer to manufacture Paxlovid in Kalamazoo

Chemical & Engineering News, 2022
openaire   +1 more source

Paxlovid Drug Interaction Screening Checklist Updated

JAMA, 2022
openaire   +2 more sources

Dosing errors common with Paxlovid

Reactions Weekly, 2022
openaire   +1 more source

Paxlovid: risk of drug interactions

Reactions Weekly, 2023
openaire   +1 more source

Effect of the Paxlovid on Glomerular Disease Patients

Journal of the American Society of Nephrology, 2023
Miguel Uriol Rivera, Estela M. Ródenas, Felipe I. Ojeda, Sonia Jimenez, Aina Obrador   +4 more
openaire   +1 more source

Is Paxlovid Still Worth It?

Clinical Infectious Diseases
Jeremy Samuel Faust, Gideon Meyerowitz-Katz   +1 more
openaire   +2 more sources